Study design and endpoints
The relative bioavailability of the tablet in reference to the PIC formulation was characterized in a crossover PK study design (Supplementary Fig. The primary endpoints were the ratio of geometric means of the following PK parameters for TAK-931 tablets in reference to PIC and associated 2-sided 90% confidence intervals (CIs): maximum observed plasma concentration (C